vs
Side-by-side financial comparison of ADAMAS TRUST, INC. (ADAM) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
ADAMAS TRUST, INC. is the larger business by last-quarter revenue ($43.2M vs $23.0M, roughly 1.9× Intellia Therapeutics, Inc.). ADAMAS TRUST, INC. runs the higher net margin — 124.0% vs -416.2%, a 540.1% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 61.6%). ADAMAS TRUST, INC. produced more free cash flow last quarter ($125.9M vs $-69.4M). Over the past eight quarters, ADAMAS TRUST, INC.'s revenue compounded faster (55.5% CAGR vs -10.8%).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
ADAM vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $43.2M | $23.0M |
| Net Profit | $53.5M | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | — | -428.9% |
| Net Margin | 124.0% | -416.2% |
| Revenue YoY | 61.6% | 78.8% |
| Net Profit YoY | 270.5% | 25.7% |
| EPS (diluted) | $0.45 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $43.2M | $23.0M | ||
| Q3 25 | $36.6M | $13.8M | ||
| Q2 25 | $36.4M | $14.2M | ||
| Q1 25 | $33.1M | $16.6M | ||
| Q4 24 | $26.7M | $12.9M | ||
| Q3 24 | $20.2M | $9.1M | ||
| Q2 24 | $19.0M | $7.0M | ||
| Q1 24 | $17.9M | $28.9M |
| Q4 25 | $53.5M | $-95.8M | ||
| Q3 25 | $44.8M | $-101.3M | ||
| Q2 25 | $8.5M | $-101.3M | ||
| Q1 25 | $42.2M | $-114.3M | ||
| Q4 24 | $-31.4M | $-128.9M | ||
| Q3 24 | $42.8M | $-135.7M | ||
| Q2 24 | $-15.6M | $-147.0M | ||
| Q1 24 | $-57.9M | $-107.4M |
| Q4 25 | — | -428.9% | ||
| Q3 25 | — | -808.9% | ||
| Q2 25 | 11.7% | -772.2% | ||
| Q1 25 | — | -726.6% | ||
| Q4 24 | -119.0% | -1059.9% | ||
| Q3 24 | — | -1589.0% | ||
| Q2 24 | -124.7% | -1998.6% | ||
| Q1 24 | -448.8% | -394.0% |
| Q4 25 | 124.0% | -416.2% | ||
| Q3 25 | 122.5% | -735.2% | ||
| Q2 25 | 23.4% | -710.8% | ||
| Q1 25 | 127.4% | -687.6% | ||
| Q4 24 | -117.5% | -1001.2% | ||
| Q3 24 | 211.7% | -1489.5% | ||
| Q2 24 | -81.9% | -2112.6% | ||
| Q1 24 | -324.1% | -371.3% |
| Q4 25 | $0.45 | $-0.81 | ||
| Q3 25 | $0.36 | $-0.92 | ||
| Q2 25 | $-0.04 | $-0.98 | ||
| Q1 25 | $0.33 | $-1.10 | ||
| Q4 24 | $-0.46 | $-1.27 | ||
| Q3 24 | $0.36 | $-1.34 | ||
| Q2 24 | $-0.29 | $-1.52 | ||
| Q1 24 | $-0.75 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $210.3M | $449.9M |
| Total DebtLower is stronger | $735.8M | — |
| Stockholders' EquityBook value | $1.4B | $671.4M |
| Total Assets | $12.6B | $842.1M |
| Debt / EquityLower = less leverage | 0.52× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $210.3M | $449.9M | ||
| Q3 25 | $185.3M | $511.0M | ||
| Q2 25 | $160.4M | $459.7M | ||
| Q1 25 | $177.1M | $503.7M | ||
| Q4 24 | $167.4M | $601.5M | ||
| Q3 24 | $195.1M | $658.1M | ||
| Q2 24 | $235.5M | $691.1M | ||
| Q1 24 | $226.9M | $791.3M |
| Q4 25 | $735.8M | — | ||
| Q3 25 | $766.6M | — | ||
| Q2 25 | $653.0M | — | ||
| Q1 25 | $654.4M | — | ||
| Q4 24 | $573.2M | — | ||
| Q3 24 | $699.4M | — | ||
| Q2 24 | $800.7M | — | ||
| Q1 24 | $1.0B | — |
| Q4 25 | $1.4B | $671.4M | ||
| Q3 25 | $1.4B | $748.4M | ||
| Q2 25 | $1.4B | $715.3M | ||
| Q1 25 | $1.4B | $779.9M | ||
| Q4 24 | $1.4B | $872.0M | ||
| Q3 24 | $1.4B | $962.6M | ||
| Q2 24 | $1.4B | $971.1M | ||
| Q1 24 | $1.5B | $1.0B |
| Q4 25 | $12.6B | $842.1M | ||
| Q3 25 | $12.4B | $925.3M | ||
| Q2 25 | $10.6B | $898.9M | ||
| Q1 25 | $10.0B | $986.2M | ||
| Q4 24 | $9.2B | $1.2B | ||
| Q3 24 | $8.9B | $1.2B | ||
| Q2 24 | $8.2B | $1.2B | ||
| Q1 24 | $7.4B | $1.3B |
| Q4 25 | 0.52× | — | ||
| Q3 25 | 0.55× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.56× | — | ||
| Q1 24 | 0.67× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $134.0M | $-69.3M |
| Free Cash FlowOCF − Capex | $125.9M | $-69.4M |
| FCF MarginFCF / Revenue | 291.6% | -301.6% |
| Capex IntensityCapex / Revenue | 18.9% | 0.5% |
| Cash ConversionOCF / Net Profit | 2.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $134.0M | $-69.3M | ||
| Q3 25 | $6.9M | $-76.9M | ||
| Q2 25 | $39.2M | $-99.6M | ||
| Q1 25 | $25.8M | $-148.9M | ||
| Q4 24 | $14.1M | $-85.2M | ||
| Q3 24 | $-922.0K | $-84.8M | ||
| Q2 24 | $-993.0K | $-58.2M | ||
| Q1 24 | $-13.1M | $-120.7M |
| Q4 25 | $125.9M | $-69.4M | ||
| Q3 25 | — | $-76.9M | ||
| Q2 25 | — | $-99.9M | ||
| Q1 25 | — | $-149.7M | ||
| Q4 24 | $-10.6M | $-86.2M | ||
| Q3 24 | $-8.6M | $-86.1M | ||
| Q2 24 | $-8.6M | $-59.2M | ||
| Q1 24 | $-19.1M | $-123.2M |
| Q4 25 | 291.6% | -301.6% | ||
| Q3 25 | — | -558.2% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | — | -900.1% | ||
| Q4 24 | -39.6% | -669.4% | ||
| Q3 24 | -42.3% | -945.2% | ||
| Q2 24 | -44.9% | -850.9% | ||
| Q1 24 | -107.0% | -425.7% |
| Q4 25 | 18.9% | 0.5% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | 92.3% | 7.6% | ||
| Q3 24 | 37.7% | 14.0% | ||
| Q2 24 | 39.7% | 14.5% | ||
| Q1 24 | 33.5% | 8.7% |
| Q4 25 | 2.50× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 4.59× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.02× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADAM
| Other | $19.6M | 45% |
| Constructive Loans LLC | $14.4M | 33% |
| Multifamily | $9.1M | 21% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
